Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy

Kanke,Yasuyuki; Saito,Motonobu; Abe,Noriko; Saito,Katsuharu; Goto,Akiteru; Ohtake,Tohru; Murakami,Yoshinori; Kono,Koji

doi:10.3892/ol.2018.9727

Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy

Authors:
- Yasuyuki Kanke
- Motonobu Saito
- Noriko Abe
- Katsuharu Saito
- Akiteru Goto
- Tohru Ohtake
- Yoshinori Murakami
- Koji Kono
View Affiliations

Affiliations: Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Fukushima 960‑1295, Japan, Department of Breast Surgery, Fukushima Medical University School of Medicine, Fukushima, Fukushima 960‑1295, Japan, Department of Cellular and Organ Pathology, Akita University Graduate School of Medicine, Akita, Akita 010‑8543, Japan, Division of Molecular Pathology, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan
Published online on: November 19, 2018 https://doi.org/10.3892/ol.2018.9727
Pages: 921-926
Copyright: © Kanke et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple negative breast cancer (TNBC) is defined by a lack of ER, PgR, and HER2 expression, and to date there have been no significant advances in treatment by targeted therapies against those molecules. Therefore, primary systemic therapy (PST) followed by surgery is the standard therapy for patients with advanced TNBC. According to gene expression analysis, TNBC has a distinct profile when compared with non‑TNBC, suggesting that a unique gene affects the treatment efficacy of PST. Cell adhesion molecule (CADM) genes encode an immunoglobulin superfamily molecule involved in cell‑to‑cell adhesion in a variety of human epithelial cells. While it has been reported that inactivation of CADM1 and CADM4 serves a pivotal role in the progression of breast cancer, a full analysis has not been completed for TNBC. Previous studies have reported that CADM1 and CADM4 expression is less likely to be decreased in TNBC than in non‑TNBC. In the present study, CADM1 and CADM4 expression was evaluated in patients with TNBC who had received PST. The present study revealed that loss or weak expression of CADM1 was frequently observed in non‑pathological complete response patients. Furthermore, while the majority of TNBC cases exhibited high CADM1 expression, a small number of cases exhibited low CADM1 expression and low therapeutic response of PST for TNBC. These results suggest that CADM1 has a pivotal role in anti‑PST efficacy in patients with TNBC.

View Figures

View References

1	Berruti A, Generali D, Bertaglia V, Brizzi MP, Mele T, Dogliotti L, Bruzzi P and Bottini A: Intermediate endpoints of primary systemic therapy in breast cancer patients. J Natl Cancer Inst Monogr. 2011:142–146. 2011. View Article : Google Scholar : PubMed/NCBI
2	Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, et al: International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr. 2011:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B and Winer EP: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 26:814–819. 2008. View Article : Google Scholar : PubMed/NCBI
4	Weigelt B, Baehner FL and Reis-Filho JS: The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade. J Pathol. 220:263–280. 2010.PubMed/NCBI
5	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
6	Turner NC and Reis-Filho JS: Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 19:6380–6388. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ito A, Ichiyanagi N, Ikeda Y, Hagiyama M, Inoue T, Kimura KB, Sakurai MA, Hamaguchi K and Murakami Y: Adhesion molecule CADM1 contributes to gap junctional communication among pancreatic islet α-cells and prevents their excessive secretion of glucagon. Islets. 4:49–55. 2012. View Article : Google Scholar : PubMed/NCBI
8	Murakami Y: Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer. Oncogene. 21:6936–6948. 2002. View Article : Google Scholar : PubMed/NCBI
9	Goto A, Niki T, Chi-Pin L, Matsubara D, Murakami Y, Funata N and Fukayama M: Loss of TSLC1 expression in lung adenocarcinoma: Relationships with histological subtypes, sex and prognostic significance. Cancer Sci. 96:480–486. 2005. View Article : Google Scholar : PubMed/NCBI
10	Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM and Huang DP: Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 38:170–178. 2003. View Article : Google Scholar : PubMed/NCBI
11	Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T, Kawata S, Kimura W, Nishizuka S and Murakami Y: Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res. 93:857–860. 2002. View Article : Google Scholar : PubMed/NCBI
12	Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, Hruban R, Offerhaus JG and Goggins M: Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther. 1:293–296. 2002. View Article : Google Scholar : PubMed/NCBI
13	Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T, Shuin T, et al: Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res. 93:605–609. 2002. View Article : Google Scholar : PubMed/NCBI
14	Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ and Snijders PJ: TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst. 96:294–305. 2004. View Article : Google Scholar : PubMed/NCBI
15	Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F and Murakami Y: Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer. 19:242–252. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, et al: TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 27:427–430. 2001. View Article : Google Scholar : PubMed/NCBI
17	Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y and Murakami Y: Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer. 130:1329–1337. 2012. View Article : Google Scholar : PubMed/NCBI
18	Jang SM, Sim J, Han H, Ahn HI, Kim H, Yi K, Jun YJ, Rehman A, Chung MS, Jang K and Paik SS: Clinicopathological significance of CADM4 expression in invasive ductal carcinoma of the breast. J Clin Pathol. 66:681–686. 2013. View Article : Google Scholar : PubMed/NCBI
19	Jang SM, Han H, Jun YJ, Jang SH, Min KW, Sim J, Ahn HI, Lee KH, Jang KS and Paik SS: Clinicopathological significance of CADM4 expression, and its correlation with expression of E-cadherin and Ki-67 in colorectal adenocarcinomas. J Clin Pathol. 65:902–906. 2012. View Article : Google Scholar : PubMed/NCBI
20	Saito M, Goto A, Abe N, Saito K, Maeda D, Ohtake T, Murakami Y and Takenoshita S: Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer. Oncol Lett. 15:2401–2406. 2018.PubMed/NCBI
21	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
22	Sobin LH, Gospodarowicz M and Wittekind Ch: International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; Oxford, UK: 2010
23	Saito M, Matsuzaki M, Sakuma T, Katagata N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S and Nomizu T: Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS. Breast Cancer. 21:140–145. 2014. View Article : Google Scholar : PubMed/NCBI
24	Wikman H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal M, Iljin K, et al: Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget. 5:3076–3087. 2014. View Article : Google Scholar : PubMed/NCBI
25	Abramson VG, Lehmann BD, Ballinger TJ and Pietenpol JA: Subtyping of triple-negative breast cancer: Implications for therapy. Cancer. 121:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
26	Abramson VG and Mayer IA: Molecular heterogeneity of triple negative breast cancer. Curr Breast Cancer Rep. 6:154–158. 2014. View Article : Google Scholar : PubMed/NCBI
27	Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, et al: Gene aberration profile of tumors of adolescent and young adult females. Oncotarget. 9:6228–6237. 2017.PubMed/NCBI
28	Greaves M and Maley CC: Clonal evolution in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
29	Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al: Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 346:256–259. 2014. View Article : Google Scholar : PubMed/NCBI
30	de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, et al: Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 346:251–256. 2014. View Article : Google Scholar : PubMed/NCBI